Accueil   Diary - News   All news Nosopharm obtains US patent for NOSO-502, a first-inclass novel antibiotic

Nosopharm obtains US patent for NOSO-502, a first-inclass novel antibiotic

 

Patent secures US market exclusivity for Nosopharm and covers numerous chemical analogs, reinforcing protection of NOSO-502’s chemical space

 


Lyon, France, April 22, 2020 – Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces it has been granted a US patent for NOSO-502. NOSO-502 is Nosopharm’s first clinical candidate in a new class of antibiotics called Odilhorhabdins, aimed at eradicating resistant bacteria. This patent secures Nosopharm’s market exclusivity rights in the US, the leading pharmaceutical market. It also covers numerous chemical analogs - the chemical space of NOSO-502 – thereby reinforcing its protection against exploitation by competitors.

 

 

Read the press release